Brexit - risks and opportunities for the life science sector
8 December 2017
The Health Committee hears from medical research charities and industry about the risks and opportunities Brexit poses for research and development, clinical trials, manufacturer and supply of medical products and patient access to new treatments.
- Watch Parliament TV: Brexit – medicines, medical devices and substances of human origin
- Inquiry: Brexit – medicines, medical devices and substances of human origin
- Health Committee
Witnesses
Tuesday 12 December 2017 in the Thatcher Room, Portcullis House
At 11.30am
- Dr Jane Spink, Chief Executive, Genetic Alliance UK
- Dr Beth Thompson MBE, Head of UK and EU Policy, The Wellcome Trust
- Aisling Burnand MBE, Chief Executive, Association of Medical Research Charities
At 12.30pm
- Steve Bates, Chief Executive, BioIndustry Association
- Leslie Galloway, Chairman, Ethical Medicines Industry Group
- Suzanne Halliday, Head of Medical Devices, British Standards Institution
- Doris-Ann Williams MBE, Chief Executive, British In-vitro Diagnostics Association
Further information
Image: iStockphoto